Palbociclib treatment in patients with HR+/HER2- advanced or metastatic breast cancer and visceral metastasis: A systematic literature review.

ABSTRACT:

Background

Visceral metastasis is prevalent among patients with advanced/metastatic breast cancer (ABC) and is a prognostic indicator of poor survival. We conducted a systematic literature review of the evidence for palbociclib plus endocrine therapy (ET) in patients with hormone receptor-positive/human epidermal growth factor receptor 2-negative (HR+/HER2-) ABC and visceral metastasis.

Methods

PubMed, EMBASE, Cochrane Library, and relevant conference proceedings were searched through September 2023. Phase 2/3 randomized clinical trials (RCTs) and real-world evidence (RWE) studies evaluating efficacy/effectiveness, safety, and health-related quality-of-life (QoL) of palbociclib plus ET were included.

Results

Qualitative synthesis was conducted on 70 articles; 24 repor

SUBMITTER: Radosa JC 

PROVIDER: S-EPMC12683142 | biostudies-literature | 2025 Dec

REPOSITORIES: biostudies-literature